Table 1.
Demographic characteristics of (1) study population by SARS-CoV-2 status (2) RT-PCR cases (positive) and controls (negative).
| Characteristics |
SARS-CoV-2 status |
Matched sets for COVID-19 infection |
||
|---|---|---|---|---|
|
Test positive (n = 5100) (%) |
Test negative (n = 9099) (%) |
Cases (n = 2644) (%) |
Controls (n = 2644) (%) |
|
| Sex | ||||
| Female | 2418 (47.4) | 3550 (39.0) | 1193 (45.1) | 1193 (45.1) |
| Male | 2682 (52.6) | 5549 (61.0) | 1451 (54.9) | 1451 (54.9) |
| Age Groups | ||||
| 18–39 | 3283 (64.4) | 5897 (64.8) | 1851 (70.0) | 1851 (70.0) |
| 40–59 | 1389 (27.2) | 2368 (26.0) | 616 (23.3) | 616 (23.3) |
| >60 | 428 (8.4) | 834 (9.2) | 177 (6.7) | 177 (6.7) |
| Nationality | ||||
| Malaysian | 4661 (91.4) | 8713 (95.8) | 2554 (96.6) | 2554 (96.6) |
| Non-Malaysian | 439 (8.6) | 386 (4.2) | 90 (3.4) | 90 (3.4) |
| Reason for testing | ||||
| Contact tracing | 2226 (43.6) | 965 (10.6) | 790 (29.9) | 790 (29.9) |
| Mandatory testing | 2317 (45.4) | 7705 (84.7) | 1567 (59.3) | 1567 (59.3) |
| Symptomatic | 527 (10.3) | 429 (4.7) | 287 (10.9) | 287 (10.9) |
| Vaccination status* | ||||
| 1 dose BNT-162b2 vaccine | 4393 (86.1) | 8276 (91.0) | 2194 (83.0) | 2362 (89.3) |
| 2 doses BNT-162b2 vaccine | 3882 (76.1) | 7917 (87.0) | 1983 (75.0) | 2233 (84.5) |
| Unvaccinated | 707 (13.9) | 823 (9.0) | 450 (17.0) | 282 (10.7) |
| Clinical staging (Category) | ||||
| 1 | 4201 (82.4) | – | 1988 (75.2) | – |
| 2 | 276 (5.4) | – | 183 (6.9) | – |
| 3 | 65 (1.3) | – | 34 (1.3) | – |
| 4 | 28 (0.5) | – | 19 (0.7) | – |
| 5 | 139 (2.7) | – | 92 (3.5) | – |
| Missing | 391 (7.7) | – | – | – |
| Week of testing | ||||
| Week 1–5 | 86 | 693 | 75 | 75 |
| Week 6–10 | 50 | 493 | 45 | 45 |
| Week 11–15 | 2593 | 1759 | 1362 | 1362 |
| Week 16–20 | 2039 | 1351 | 876 | 876 |
| Week 21–25 | 168 | 1459 | 133 | 133 |
| Week 26–30 | 100 | 2193 | 96 | 96 |
| Week 31–35 | 64 | 1133 | 57 | 57 |
* Vaccination status does not take into account 14 days after second dose for fully vaccinated.